Get to Know Dr. Shanel Bhagwandin
Dr. Shanel Bhagwandin is the medical director of Gastrointestinal Surgical Oncology at Jupiter Medical Center.
He remains affiliated with the renowned Icahn School of Medicine at Mount Sinai in New York, where he previously worked. He continued his role at Mount Sinai as medical director of Surgical Oncology Network Development. Bhagwandin is also an assistant professor of surgical oncology at the Icahn School of Medicine.
He has expertise in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, known as HIPEC. This combination has proven effective for treating peritoneal mesothelioma and several other abdominal malignancies.
Bhagwandin graduated from Lake Erie College of Osteopathic Medicine. He did a residency at the University of Illinois, along with a fellowship and an internship at Mount Sinai. His professional memberships include the Society of Surgical Oncology, Americas Hepato-Pancreato-Biliary Association and the American College of Surgery.
Specialties of Dr. Shanel Bhagwandin
- Peritoneal mesothelioma
- Stomach cancer
- Esophageal cancer
Dr. Shanel Bhagwandin’s Experience and Medical Education
- Jupiter Medical Center
- Lake Erie College of Osteopathic Medicine (M.D.)
- University of Illinois Hospital & Health Sciences System (Residency)
- Icahn School of Medicine at Mount Sinai (Fellowship)
Publications of Dr. Shanel Bhagwandin
- Feferman, Y. et al. (2019, February). Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience. Annals of Surgical Oncology.
- Feferman, Y. et al. (2017, December). Conflicting Data on the Incidence of Leukopenia and Neutropenia After Heated Intraperitoneal Chemotherapy with Mitomycin C. Annals of Surgical Oncology.
- Kim, J., Bhagwandin, S. & Labow, D.M. (2017, June). Malignant peritoneal mesothelioma: a review. Annals of Translational Medicine.
Thank you for your feedback. Would you like to speak with a Patient Advocate?